Rise and shine. Another busy day is on the way. And this appears it will also be a steamy one here on the Pharmalot campus, where the short people are sleeping in and the official mascots are chatting around the water bowl. As for us, we are motoring along thanks to a few cups of stimulation. As always, you are invited to join us. And of course, here are a few items of interest to help you along. Have a great day, everyone, and do keep in touch …
Medivation signed confidentiality agreements with Sanofi and other drug makers, including Pfizer and Celgene, that are interested in buying the company, the Wall Street Journal writes. At the same time, Medivation rejected a sweetened bid from Sanofi, which initially made a $9.3 billion hostile offer. Sanofi had increased its offer from $52.50 a share to $58.00, plus another $3.00 in the form of a contingent value right.
Quest Life Sciences may appeal a decision by the UK’s Medicines and Healthcare products Regulatory Agency to suspend marketing for drugs that were approved based on its clinical studies, Reuters reports. The regulator suspended marketing authorizations over data integrity concerns at the contract research organization, which maintains its quality control has been updated since the 2014 inspection.
You could increase the quota to 1000 addicts/doctor. Most psychiatrists who are not addiction specialists don’t want the paperwork headache along with the 3am phone calls from junkies who ran out of bupe. Most junkies are not serious about recovery and view the shrinks as just another way to get their supply, with the added inconvenience of having to make an appointment.
The Roche item brings an interesting thought to mind. SUI is neither an EU nor EEA member but it still moves along. I suppose the UK and its pharma industry will survive Brexit…. but Scotland leaving them would be something else. We’ll leave Irish reunification for another time.
Comments are closed.